Toi, Masakazu

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,744

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,680

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 991

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 813

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 685

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 364

UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α

Goto, Y., Zeng, L., Yeom, C. J., Zhu, Y., Morinibu, A., Shinomiya, K., Kobayashi, M., Hirota, K., Itasaka, S., Yoshimura, M., et al. (2015) · Nature Communications

Ubiquitin and proteasome pathwaysCancer, Hypoxia, and Metabolism

Cited by 229

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Yamauchi, H., Toi, M., Takayama, S., Nakamura, S., Takano, T., Cui, K., Campbell, C., De Vos, L., Geyer, C., & Tutt, A. (2023) · Breast Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 13